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Introduction
In 2005 the results of the Sirocco II trial, comparing the
safety and efficacy of the sirolimus-eluting stents and bare
nitinol stents in the superficial femoral artery were pub-
lished [1]. In this study, finally, no statistically significant
differences in any of the outcomes could be shown. Since
then there has been a complete revolution in drug-eluting
technologies for peripheral vessels. There have been fierce
debates about coatings, types of drugs, release profiles, and
doses. The introduction of the drug-eluting balloons pro-
voked a new debate about not leaving something behind.
Unfortunately, the majority of the literature is about these
technical details and safety and there are only a few ran-
domized trials available for clinical analysis. Although the
results of all these new devices have been presented as very
successful or at least very promising, there were also a few
critical voices at the background [2]. These voices however
have not had much attention, moreover they were seen as
silly twaddle or flawed arguments.
How Does Drug-Eluting Technology Work
on the Vessel wall?
Both balloon expansion and stent placement provoke sev-
ere damage to the vascular endothelium. This single cell
layer needs to be repaired to avoid local thrombotic events
and once the endothelium is recovered, this also supports
quiescence of the underlying smooth muscle cells. Healthy
and functional endothelium is crucial to provide an anti-
coagulant surface and it delimits smooth muscle cell
growth and thus neointimal lesion formation [3]. The ideal
drug for local delivery should inhibit the proliferation of
smooth muscle cells and simultaneously promote
endothelial cell growth.
The most frequently used drugs for local vascular
application by balloons and stents are the cytostatic drug
paclitaxel and the immunosuppressive medicine sirolimus
and its derivatives [4]. Paclitaxel enters the cell to bind and
stabilize tubulin polymers thereby disturbing regular
metaphase spindle formation during cell division. As a
result, chromosomes cannot segregate and cell division is
blocked and this is often followed by cell apoptosis,
making paclitaxel an effective drug in several cancer
therapies. Initially sirolimus, also known as rapamycin,
was shown to block the activation of T and B cells through
inhibition of the so-called mechanistic Target of Rapa-
mycin (mTOR) intracellular signaling pathway. Later on, it
became clear that inhibition of mTOR also compromises
the proliferation of many different cell types. Since then,
multiple sirolimus analogues have been developed such as
everolimus, tacrolimus, and biolimus to treat specific types
of cancer. Paclitaxel and limus derivatives inhibit the
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proliferation of smooth muscle cells very efficiently,
explaining their un-surpassed effectiveness in preventing
intimal hyperplasia. The mere fact that these drugs also
ameliorate the recovery of the endothelial cell layer after
intervention, indicates that there still is a need for more
cell-type-specific drugs in drug-eluting technology to
improve safety and reduce thrombosis risk. Given that local
balloon-mediated delivery involves application of a single
dose of drug in the vessel wall and that stents release drugs
for a period of only 2–4 weeks, it is remarkable that even
after 12 months there is limited intimal hyperplasia and
incomplete endothelialization of the treated vessel segment
[3]. This could point in the direction of permanent vessel
wall damage with even possible future implications. There
are some new technologies underway that potentially will
work more targeted, not blocking the endothelial cell
repair, but further clinical investigations need to be done
first [5, 6].
Where Do We Stand?
By now there is enough good evidence to show that drug-
eluting technology does have an impact on the vessel wall
and intimal hyperplasia. Two high-quality systematic
reviews show improved primary vessel patency (high-
quality evidence), binary restenosis rate (moderate quality
evidence), and target lesion revascularization (low-quality
evidence) for up to 12 months [2, 7]. However, for real
endpoints that matters to the patients’ health and wellbe-
ing like improved walking distance, Quality of life,
amputation free survival, death, or change in Rutherford
category during 12 months follow-up no improvement
could be shown in these two meta-analyses. A swift
interpretation of these data could lead to the conclusion
that better patency does not translate into better outcome
and that drug-eluting technology is yet another endovas-
cular myth.
But is this really true or are we to early with our
judgement? One of the main flaws in almost all studies on
drug-eluting technology are the inclusion criteria and study
endpoints. If one includes two completely different types of
patients, one group with claudication and one group with
critical limb ischemia (CLI) in a randomized trial and then
applies the same endpoints, like amputation or improved
walking distance, there will never be any difference. 95 %
of the patients with claudication are never at risk for
amputation and CLI patients cannot be measured for
improved walking distance. This is also confirmed by
another high-quality meta-analysis showing statistically
significant superiority of drug-eluting stents over bare
metal stents for late lumen loss and TLR, but again with no
benefit in amputation or mortality [8].
The LEVANT trial comparing drug-eluting ballooning
(DEB) with percutaneous transluminal angioplasty and
stent on indication, in the superficial femoral artery with a
2:1 randomization, included 148 patients with mild clau-
dication, 290 patients with severe claudication, and 38
patients with ischemic rest pain. There were no patients
with tissue loss included (Rutherford 5 and 6) [9]. No
difference in meaningful clinical endpoints between both
groups was seen [9]. We know that patients with mild
claudication do fine without any intervention and that in
patients with critical limb ischemia outcome is not always
directly related to infrapopliteal vessel disease or ABI.
Also not every patient with rest pain is at high risk for
amputation. This study is therefore flawed because of the
wrong inclusion and the wrong endpoints for this targeted
group, and therefore this study was unable to show clinical
benefit.
In the PADI study, which is a randomized trial to
compare DES to PTA with or without bare stent, only
patients with critical limb ischemia (Rutherford cate-
gory C4) and infrapopliteal lesions were included [10].
The major amputation rate remained lower in the DES
group until 2 years post-treatment, with a trend toward
significance (P = 0.066). The fact that it did not reach
significance could be because of the small sample size, the
use of a sub-optimal coronary stent in the DES group
versus a none coronary stent in the PTA group, and the fact
that no sub-analysis for the grades of ischemia was possible
because of the small sample size.
The important lesson to learn is that included patients
and endpoints must match to be able to obtain a meaningful
result of any trial.
Conclusion
The statement that drug-eluting technology gives better
clinical outcome compared to standard pta and that this is a
proven technology is not supported by the current litera-
ture. However, the statement that drug-eluting technology
does not work is also incorrect, moreover there is enough
evidence that shows the inhibiting effects on the repair of
vessel wall cells after pta. The evidence that drug-eluting
techniques have a positive effect on the inhibition of inti-
mal hyperplasia still not translates into a better clinical
outcome. TLR, VLR, and clinically driven re-intervention
are proxy endpoints and a major concern regarding its
questionable relevance and deceiving nature [11]. We still
just need good studies with proper patient selection and
matching clinically relevant endpoints. The PADI study is
an example of how such a study should be designed. Is this
ever going to happen? The main stakeholders are satisfied
with the current state of evidence, the majority of
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interventional radiologists and vascular surgeons believe in
drug-eluting technology, as it became clear from the
audience pooling at the 2016 Charing Cross meeting
(London, UK). So there is no urgent need to start a new
study as the goals for the industry and most physicians
have been obtained. The alarming publicity coming from
the IN.PACT DEEP trial showing a trend towards higher
amputation in the DEB—arm will also not be a motivation
for industry to support another trial like this [12]. Although
this increase in amputation in the DEB—arm of the study
could be explained by other external circumstances [13].
But without proper clinical evidence the main stakeholder
in this discussion, the patient, is the one who finally pays
the extra costs for this new technology without any proof of
clinical efficacy. And that conclusion by itself should be a
motivation for every interventionalist to get the evidence
on the table as soon as possible.
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